Nav: Home

Cost savings from growth hormone insurance strategies not passed on to patients

March 24, 2019

NEW ORLEANS--Increasingly aggressive insurance strategies have lowered the total costs and insurance costs of growth hormone drugs, but those savings are not being passed on to patients, according to new research to be presented Sunday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.

In 2003, the U.S. Food and Drug Administration approved growth hormone treatment for idiopathic short stature (children who are short for no known cause). This expanded potential eligibility for treatment to the shortest 1.2 percent of the U.S. population, at a potential estimated national cost of $40 billion.

"However, in subsequent years, health insurance companies imposed greater barriers to reimbursement for growth hormone treatment," said lead researcher Adda Grimberg, M.D., of the Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania in Philadelphia, Penn. Insurers have instituted formularies--lists of drugs that are covered by the insurance plan--that exclude all but a few brands of growth hormone drugs, and change these lists frequently based on prices negotiated with manufacturers, forcing patients to switch brands during their course of treatment. Insurers have also adopted more stringent criteria for coverage, and many no longer cover growth hormone treatment for idiopathic short stature.

Grimberg and her co-author Genevieve P. Kanter, Ph.D., of the University of Pennsylvania, examined how use of growth hormone by U.S. youth changed over time. Using a database of 18 million individuals enrolled in commercial health plans, they examined changes in use and expenditures between 2001 and 2016. They focused on the 38,857 beneficiaries up to age 18 treated with growth hormone who had six or more months of insurance coverage in any year between 2001 and 2016.

The number of members with growth hormone prescriptions per 10,000 beneficiaries under age 18 rose steadily from 5.1 in 2001 to 14.6 in 2016, without a dramatic change around 2003, the year the FDA approved coverage for idiopathic short stature. Progressive restrictions on growth hormone coverage imposed by insurers and stricter formulary rules appear to have succeeded in lowering the total cost and insurer cost of treatment. However, those savings were not passed on to patients, who also were forced to switch drug brands as insurance companies changed their formularies.

While total growth hormone expenditures per patient decreased by 27 percent and the estimated insurance-paid amount decreased by 28 percent, average copayments, deductibles and total patient financial burden increased by 161 percent. Between 2001 and 2007, beneficiaries switching growth hormone brands at least once in the year ranged from 1.4 percent to 3.6 percent. After 2007, the range rose to 5.1 percent to 8.8 percent, with 25.6 percent switching in 2009 and 13.9 percent switching in 2015.

"These patterns are consistent with broader U.S. trends of increased patient cost-sharing and aggressive use of formularies and coverage restrictions to limit insurer costs from high specialty drug prices," Grimberg said. "The rising patient costs of insulin have emerged as an important health care concern in recent days, prompting Congressional hearings and legislative review. Our research shows that growth hormone, another endocrine medication like insulin, is costing patients more, even as costs to insurers have declined."

Grimberg noted that the patient burden of growth hormone brand switches and insurance denials/appeals is a source of great distress for patient families seeking evaluation and treatment of short stature. "Because the different growth hormone brands are delivered in different pen devices, insurance-mandated brand switches during the years a patient is treated with growth hormone require retraining on proper administration, so the process is more complicated than simply switching from one pill to another," she said.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at Follow us on Twitter at @TheEndoSociety and @EndoMedia.

The Endocrine Society

Related Growth Hormone Articles:

Growth hormone plays key role in early puberty, breast cancer risk
Girls who enter puberty early in life--as measured by early breast development and age of first menstrual period--have a longer window of susceptibility to breast cancer.
Human growth hormone treatment after ACL injury may prevent loss of muscle strength
A new study finds the use of HGH treatment in patients that have undergone ACL reconstructive surgery may prevent the loss of muscle strength and weakness.
Liver surgery success boosted by growth hormone
Growth hormone has been identified as playing a key role in reducing inflammation and increasing survival rates following liver surgery.
Growth hormone acts to prevent weight loss
A Brazilian study shows that, like leptin, growth hormone contributes directly to energy conservation when the body loses weight.
Cost savings from growth hormone insurance strategies not passed on to patients
Increasingly aggressive insurance strategies have lowered the total costs and insurance costs of growth hormone drugs, but those savings are not being passed on to patients, according to new research to be presented Sunday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
Patients bear increased financial burden for growth hormone treatment despite FDA approval
Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time.
Growth hormone may provide new hope for stroke survivors
Less fatigue and better recovery of cognitive abilities such as learning and memory.
FASEB Science Research Conference: Growth Hormone/Prolactin
This SRC will bring together international scientists from academia and industry for lively discussions on the latest developments in the growth hormone (GH)/prolactin (PRL) family of hormones and their clinical applications.
Low thyroid hormone before birth alters growth and development of fetal pancreas
Levels of thyroid hormone in babies influences insulin-secreting cells of the pancreas, according to a new study published in The Journal of Physiology.
When should doctors treat short children and teens with growth hormone?
When is it appropriate to treat short children with growth hormone?
More Growth Hormone News and Growth Hormone Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.